Navigation Links
New Shared Synthetic Replikin Cancer Vaccines
Date:1/22/2013

BOSTON, Jan. 22, 2013 /PRNewswire/ -- Replikins Ltd. and Brain Research Associates announced today that specific conserved genomic Replikin peptide sequences for the first time have been found to be shared among different histological cancer types, permitting the seven day synthesis of new shared cancer vaccines.

(Photo: http://photos.prnewswire.com/prnh/20130122/PH45996 )

Each of the shared Replikins was found to be present in multiple malignancies. The genomic Replikin®Count (number of Replikin genomic structures per 100 amino acids) relates quantitatively to the five year human mortality rate for each cancer type, the first genomic structures found to be so related (1) (see Figure). The lowest genomic Replikin®Counts were found in those cancers which have the lowest five year mortality rates, as in prostate and thyroid cancer; and the highest Replikin®Counts were found in glioblastoma multiforme, pancreatic and lung cancer, which have the highest mortality rates.

Genomic Replikins in cancer are quantitatively predictive of mortality rate, as recently also found by Replikins Ltd. in viral infectious disease (1-10), and these Replikin structures enable the production of effective specific synthetic vaccines in seven days (9,10). These genomic Replikins in cancer are also the basis of aids for cancer diagnosis, as the Antimalignin Antibody in Serum (AMAS)®Test, the anti-Replikin antibody test, which was shown to be elevated in all common cancers (1). This test has proved useful in helping to distinguish benign from malignant growths, when the cancer is small and barely detected by radiographic techniques, eg. as an aid in diagnosing cancer early in lung and in breast lesions (1). The AMAS®Test can now also be used as a marker to track cancer prevention by synthetic Replikins vaccines (9,10) in high risk subjects, and to track efficacy of treatment by synthetic Replikins blockers (10). 

Contact:
Anne Borsanyi
aborsanyi@replikins.com
646-320-5910
http://www.replikins.com/

References:

1. Bogoch S and Bogoch ES. Genome Replikin CountTM  Predicts Increased Lethality of Cancer. Nature Precedings doi:10.1038/npre.2012.7143.1

2. Bogoch, S. and Bogoch, E.S. Genome Replikin CountTM Predicts Increased Infectivity/Lethality of Viruses. Nature Precedings npre2012.7144. 04April 2012. 


3. Bogoch, S. and Bogoch, E.S. Prediction of specific virus outbreaks made from the increased concentration of a new class of virus genomic peptides, replikins. Nature Precedings doi:10.1038/npre.2011.6279.1.23Aug 2011. 


4. Bogoch,S. and Bogoch, ES. Bogoch Replikins Pandemic Prevention: Increase of Strain-Specific Influenza Genomic Replikin Counts, Having Predicted Outbreaks and their Location Seven Times Consecutively, Up to Two Years in Advance, Provides Time for Prevention of Pandemics. Nature Precedings.doi:10.1038/npre.2012.6952.1 01 March, 2012 


5. Bogoch, S. and Bogoch, E.S. Marked Rise in Replikin Counts in H5N1 Influenza Virus Localized to Lethality Gene pB1.Nature Precedings doi:10.1038/npre.2011.6420.1

6. Bogoch S, Bogoch ES.   Replikins Pandemic Prevention: Increase of Strain-Specific Influenza Genomic Replikin Counts, Having Predicted Outbreaks and their Location Seven Times Consecutively, Up to Two Years in Advance, Provides Time for Prevention of Pandemics.  Nature Precedings doi:10.1038/npre.2012.6952.1                                                                       

7. Report #49. Replikins Press<replikins.com>.Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer, June 19, 2012

8. Report #42,  Replikins Press<replikins.com>. UN Food and Agriculture Organization (FAO) discussion of Replikins, DVM Newsmagazine, (Sept. 8, 2011).

9. Jackwood, MW et al. Efficacy of a Replikin Peptide Vaccine against Low Pathogenicity Avian Influenza H5 Virus. Avian Diseases 53(4): 613‐617, 2009

10. Report # 17. Replikins Press<replikins.com>.Replikins Oral Vaccine Synthesized in 7 days protects 91% of Shrimp Against Lethal Virus . March 11, 2008.

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
2. Synthetic Biologics Reports Third Quarter 2012 Financial Results
3. Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
4. Taming mavericks: Stanford researchers use synthetic magnetism to control light
5. Synthetic Biologics Completes $10.8 Million Private Placement Financing
6. Synthetic Biologics Announces $10.8 Million Financing
7. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
8. Synthetic Biology Market is Expected to Reach USD 16.7 Billion Globally in 2018: Transparency Market Research
9. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
10. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
11. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded coverage of ... newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and ... synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
Breaking Biology News(10 mins):